A Swiss Army Knife for CTLs  by Friedl, Peter & Weigelin, Bettina
Immunity
Previewsimmune response against cytosolic DNA
(Figure 1). In this model, microbial DNA
is detected by cGAS, which catalyzes
synthesis of cGAMP from GTP and ATP.
cGAMP binds to STING (MITA), which is
also associated with an ER-associated
modulator called ZDHHC1 (Zhou et al.,
2014). At this point, AMFR is recruited
to STING (MITA) by INSIG1, and then
catalyzes K27-linked polyubiquitination
of STING (MITA). The K27-linked polyubi-
quitin chains attached to STING (MITA)
provide platforms for recruitment of
TBK1, leading to activation of IRF3 and
eventual induction of type I IFNs. In addi-
tion to AMFR, other E3 ligases, including
RNF26, TRIM32, TRIM56, and RNF5,
might also positively or negatively regu-
late STING (MITA)-mediated signaling.
The most recent works by Wang et al.
(2014) and Qin et al. (2014) are significant
because they provide the first evidences
that K27- and K11-linked polyubiquitina-
tions are important for innate antiviral
response. It is possible that in addition
to STING (MITA), additional compo-
nents might also be regulated by these
types of polyubiquitinations in innate anti-
viral response. In addition to questionsmentioned earlier, some other outstanding
questions are not answered in the current
study.Forexamples,previousstudies indi-
cate that phosphorylation of STING (MITA)
at S158 regulates the recruitment of TBK1
to STING (MITA), the relationship between
this phosphorylation and AMFR-mediated
K27-linked polyubiquitination of STING
(MITA) is unknown. In addition, whether
and how AMFR-mediated K27-linked
polyubiquitination of STING (MITA) regu-
lates the downstream NF-kB activation
pathway needs to be investigated. Never-
theless, the study by Wang et al. (2014)
provides an important link for understand-
ing the molecular mechanisms of STING
(MITA)-mediated signaling and intriguing
clues for the roles of K27-linked poly-
ubiquitination in innate immune response
against DNA pathogens.ACKNOWLEDGMENTS
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Granzyme B released by leukocytes cleaves multiple intracellular substrates required for target cell lysis. In
this issue of Immunity, Prakash et al. (2014) demonstrate that granzyme B cleaves basement membrane pro-
teins and promotes cytotoxic T cell diapedesis into inflamed tissue.Interstitial migration and recirculation of
cytotoxic T cells (CTLs) is a multistep me-
chanochemial process required for im-
mune surveillance, CTL activation, and
effector function (Friedl and Weigelin,
2008). Most tissues comprise interstitial
spaces suited to support effective leuko-cyte migration; however, basement mem-
branes consist of a network of laminins,
type IV collagen, and linker proteins that
interconnect to form a protein-dense layer
that creates a viscoelastic barrier against
migrating cells. Consequently, for pas-
sage of leukocytes from the vessel lumeninto the tissue, migration through the
vascular basement membrane, termed
diapedesis, provides challenges and
requires particular abilities (Nourshargh
et al., 2010).
Using an interdisciplinary approach
combining bioinformatics, biochemistry,ecember 18, 2014 ª2014 Elsevier Inc. 873
nidogen-2,
Figure 1. Context-Dependent Substrates and Functions of GzmB
Abbreviations are as follows: BM, basement membrane; EC, endothelial cell; ECM, extracellular matrix;
and GzmB, granzyme B.
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Previewsadvanced cell biology, and intravital mi-
croscopy, Prakash et al. (2014) in this
issue of Immunity identify the cleavage
of multiple basement membrane proteins
by granzyme B (GzmB) as an important
mechanism in CTL diapedesis in vitro
and in vivo.
The search for new GzmB substrates
and functions has proven a long-standing
reward (Boivin et al., 2009). GzmB is a
serine protease expressed by CTLs, natu-
ral killer cells, activated mast cells, and
many other cell types of immune and
nonimmune origin. It is released from
secretory vesicles upon T cell receptor
activation and other triggers. The
consensus sites for GzmB cleavage are
present in many protein domains, and
accordingly, GzmB functions are broad.
Traditional roles of GzmB in cell biology
have revolved around the function of
target cell lysis. Facilitated by perforin-
mediated pores, GzmB enters into the
cytosol of target cells and induces
apoptosis by cleaving a range of intracel-
lular substrates. These include procas-
pases, antiapoptotic heat-shock pro-
teins, adaptor proteins required for cell
anchorage, and intermediate filaments
required for integrity of the nucleus
(Figure 1). In addition, hundreds of poten-
tial intra- and extracellular GzmB sub-874 Immunity 41, December 18, 2014 ª2014strates have been identified by peptide-
library screens and proteomics and
bioinformatics screens (Boivin et al.,
2009), and additional new GzmB targets
are identified and validated in Prakash
et al. (2014). These include structural ma-
trix proteins, cell-surface receptors, cyto-
kines, and growth factors, as well as
intracellular proteins involved in cell
anchorage, signaling, and cycle regula-
tion (Figure 1). Many predicted targets still
await validation as direct GzmB sub-
strates and clarification of biological rele-
vance; however, this amazing substrate
promiscuity suggests that GzmB func-
tions with strong context dependence
and has divergent outcomes for tissue ho-
meostasis, inflammation, and even tissue
destruction.
GzmB is active at neutral pH and is
therefore ideally positioned to cleave
extracellular and cytosolic proteins, as
well as other proteases, under physiolog-
ical conditions; thus, identifying specific
GzmB substrates can be challenging. By
using GzmB-deficient CTLs, Prakash
et al. (2014) directly monitored GzmB-
dependent CTL functions and identified
an unappreciated role for GzmB in CTL
trafficking and tissue homing; these func-
tions correlated with its capability to
cleave basement membrane proteinsElsevier Inc.(Prakash et al., 2014). By proteomic anal-
ysis of GzmB-cleaved proteins from 3D
reconstituted basement membrane, they
(1) confirmed known and identified previ-
ously unmapped substrates, including
ibulin-1C, peroxidasin, and laminin b2,
by mass spectrometry; (2) predicted
their cleavage sites by bioinformatics
consensus sequencemapping; and (3) re-
vealed a role for GzmB in CTL migration
across filters coated with reconstituted
basement membrane in vitro. The biolog-
ical relevance of GzmB function in CTL
diapedesis was shown in mouse models
for virus-induced peritonitis, mechanical
skin irritation, or cutaneous contact al-
lergy response, where the trafficking
defect in GzmB-deficient CTLs became
apparent by vastly diminished recruitment
of CTLs and consecutively dampened
inflammation. Because GzmB-deficient
CTLs failed to reach inflamed tissue after
adoptive transfer in GzmB wild-type
mice, a cell-intrinsic function of GzmB
was independent of GzmB expressed by
stromal cells. Thus, CTLs are self-suffi-
cient for GzmB release to achieve
transendothelial migration into sites of
inflammation.
To mechanistically explain how GzmB
supports CTL accumulation in peripheral
tissues, Prakash et al. adoptively trans-
ferred fluorescently labeled CTLs and
recorded the steps required for transen-
dothelial migration of CTLs into the
mouse cremaster muscle by intravital
multiphoton microscopy. Whereas wild-
type CTLs entered the tissue effectively,
within a few minutes, GzmB-deficient
CTLs showed a clear diapedesis delay;
however, initial rolling along the vessel
wall, firm adhesion and polarization, and
interstitial migration were unaffected.
Thus, powerful in vivo imaging delivered
mechanistic proof of the exact step
affected by GzmB deficiency. However,
at the current resolution of intravital
imaging, fine mapping of the diapedesis
step (i.e., whether CTLs were arrested
above or below the level of endothelial
cell junctions and which extent of
basement membrane remodeling was
required for effective diapedesis) could
not be resolved.
The implications of this work are three-
fold. First, GzmB directly contributes to
the transmigration of CTLs and, most
likely, other circulating cells. This confirms
granzymes as important and versatile
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Previewseffector enzymes that perform defined
tasks in a context-dependent manner.
Second, conceptually, the data suggest
that basement membranes indeed repre-
sent a conditional barrier for passenger
cells, the diapedesis of which is facilitated
by transient breakdown of basement
membrane constituents. Third, GzmB is
dispensable for CTL trafficking through
interstitial tissue, which confirms that
amoeboid migration of leukocytes occurs
independently of proteolytic tissue re-
modeling by guidance along tissue struc-
tures rather than proteolytic tissue break-
down (Salmon et al., 2012; Wolf et al.,
2003). However, given the range of poten-
tial GzmB substrates in spatial vicinity, it
remains unclear how GzmB functions
are regulated in time and space. How is
matrix degradation executed without
apoptosis induction in local bystander
cells, such as endothelial cells, during
transmigration? Likewise, the upstream
signals controlling differential GzmB
release during transendothelial migration,
cytolytic effector function, or stromal
degradation remain to be identified.
The mechanochemical mechanisms
underlying CTL diapedesis through base-
ment membranes are poorly understood
(Nourshargh et al., 2010; Ota et al.,
2009). Therefore, the model of GzmB-
mediated diapedesis offers a defined
experimental strategy to resolve the
long-standing biomechanical and molec-
ular debate on whether the basement
membrane is a veritable barrier for diape-
desing cells or just an elastic layer that
can be mechanically deformed so cells
can pass through a small pore, or both
(Nourshargh et al., 2010; Sabeh et al.,
2009). Besides GzmB, known enzymes
cleaving basement membrane compo-
nents include elastase and matrix metal-
loproteases (MMPs), which cleaveelastin, fibronectin, laminin, and collagen
IV (Ota et al., 2009; Wang et al., 2005).
Consequently, inhibition of elastase in-
hibits neutrophil transmigration during
inflammation (Wang et al., 2005), and ge-
netic ablation of MMPs can impede tu-
mor cell migration through the chorionic
allantoic membrane (Ota et al., 2009),
albeit each interference is far from com-
plete. As the most fundamental and
simplest explanation, mechanical cell
and tissue deformability might mediate
diapedesis to facilitate substantial resid-
ual migration activity in any inhibition
scheme. However, GzmB release by
activated CTLs might generate hot spots
for amplified transmigration of many cells
along once-established routes and
accelerate otherwise time-consuming
transmigration rates at baseline and
reach high interstitial CTL frequency for
full effector power.
Similar to a Swiss army knife, GzmB
acts as multifunctional, extremely versa-
tile effector for multiple purposes of pro-
tein processing. Beyond intracellular pro-
teins and basement membrane proteins,
the more than 300 putative substrates
identified by Prakash et al. (2014) confirm,
once again, a much broader context
of GzmB function. Additional putative
substrates include cytoskeletal proteins
and proinflammatory cytokines, including
interleukin-1a and transforming growth
factor b, which could cause their activa-
tion and/or release from tissue deposits
(Boivin et al., 2012). This plethora of addi-
tional potential functions of GzmB in cell
and tissue homeostasis and disease
mostly point toward amplification of
proinflammatory responses compro-
mising cell and tissue integrity, including
type I diabetes and other autoimmune
diseases, acute transplant rejection,
chronic-obstructive bronchitis, and in-Immunity 41, Dflammatory skin diseases (Boivin et al.,
2009).
Consequently, therapeutic inhibition of
GzmB might represent an unappreciated
approach to combatting autoimmunity
and chronic-destructive inflammation
by a three-fold principle of action: (1)
reducing leukocyte recruitment to tissues,
as shown here; (2) limiting inflammation-
promoting extracellular matrix break-
down; and (3) minimizing direct cyto-
toxicity. Thus, disarming the CTLs by
confiscating the Swiss army knife, like
any weapon used for the wrong purpose,
might bring peace to inflammatory
battlegrounds.
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